Acer Therapeutics Inc.
NASDAQ:ACER
0.9 (USD) • At close September 17, 2024
Overzicht | Financiële gegevens
| Bedrijfsnaam | Acer Therapeutics Inc. |
| Symbool | ACER |
| Munteenheid | USD |
| Prijs | 0.66 |
| Beurswaarde | 0 |
| Dividendpercentage | 0% |
| 52-weken bereik | 0.55 - 4.56 |
| Industrie | Biotechnology |
| Sector | Healthcare |
| CEO | Mr. Christopher Schelling |
| Website | https://www.acertx.com |
An error occurred while fetching data.
Over Acer Therapeutics Inc.
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)



